FILE:BCR/BCR-8K-20061221164539.txt.gz
EVENTS:	Material Impairments
TEXT:
ITEM: Material Impairments
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
ITEM 2.06 Material Impairments.
On December 19, 2006, C. R. Bard, Inc. (the "company") announced at its annual investor conference that it will discontinue the sale of its Tegress urinary incontinence bulking agent. On the same date, the company concluded that it will record a related charge which it anticipates will be in the range of $43 million to $47 million in the fourth quarter of 2006, substantially all of which is related to the impairment of intellectual property and is non-cash.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
December 21, 2006


